Abeona Therapeutics (ABEO) Non-Current Debt (2018 - 2026)

Abeona Therapeutics' Non-Current Debt history runs 8 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• On a quarterly basis, Non-Current Debt fell 57.32% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 57.32% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 40.07% from the prior year.
• Non-Current Debt retreated to $4.8 million in Q1 2026 per ABEO's latest filing, from $7.8 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $18.1 million in Q1 2024 and bottomed at $3.9 million in Q1 2022.
• The 4-year median for Non-Current Debt is $10.9 million (2025), against an average of $9.7 million.
• Across the five-year window, Non-Current Debt surged 224.15% in 2022 and slumped 57.32% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $4.2 million in 2022, then jumped by 213.16% to $13.0 million in 2024, then tumbled by 40.07% to $7.8 million in 2025, then tumbled by 39.15% to $4.8 million in 2026.
• Per Business Quant, the three latest ABEO Non-Current Debt figures stand at $4.8 million (Q1 2026), $7.8 million (Q4 2025), and $10.9 million (Q3 2025).